Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription

Articles published in
    May 2024
  1. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    >> Share

    April 2024
  2. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    >> Share

    November 2023
  3. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    >> Share

    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    >> Share

    October 2023
  5. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    >> Share

  6. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    >> Share

    September 2023
  7. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    >> Share

  8. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    >> Share

  9. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    >> Share

    August 2023
  10. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    >> Share

    July 2023
  11. QIN S, Chan SL, Gu S, Bai Y, et al
    Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
    Lancet. 2023 Jul 24:S0140-6736(23)00961-3. doi: 10.1016/S0140-6736(23)00961.
    >> Share

    May 2023
  12. ADAMS PC, Jeffrey G, Ryan J
    Lancet. 2023;401:1811-1821.
    >> Share

    April 2023
  13. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    >> Share

  14. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    >> Share

    February 2023
  15. ALLISON MED, Verne J, Bernal W, Clayton M, et al
    Deaths from alcohol-related liver disease in the UK: an escalating tragedy.
    Lancet. 2023;401:418-420.
    >> Share

    September 2022
  16. VOGEL A, Meyer T, Sapisochin G, Salem R, et al
    Hepatocellular carcinoma.
    Lancet. 2022 Sep 6. pii: S0140-6736(22)01200.
    >> Share

    January 2022
  17. COOKE GS, Nayagam S
    Liver disease: at the heart of public health challenges for Europe in the 21st century.
    Lancet. 2022;399:9-10.
    >> Share

  18. KLEINERT S, Horton R
    An urgent challenge for Europe: from tackling liver diseases to protecting liver health.
    Lancet. 2022;399:7-9.
    >> Share

    December 2021
  19. NHLANE R, Kreuels B, Mallewa J, Chetcuti K, et al
    Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B.
    Lancet. 2021;398:2288.
    >> Share

  20. WATTS G
    Tom Hemming Karlsen: hepatologist with a public health message.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)02746.
    >> Share

  21. KARLSEN TH, Sheron N, Zelber-Sagi S, Carrieri P, et al
    The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)01701.
    >> Share

    October 2021
  22. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    >> Share

  23. KRIEGERMEIER A, Taylor S
    Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome.
    Lancet. 2021;398:1544-1545.
    >> Share

    September 2021
  24. GINES P, Krag A, Abraldes JG, Sola E, et al
    Liver cirrhosis.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)01374.
    >> Share

  25. GURNARI C, Colak C, Zawit M, Maciejewski JP, et al
    Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria.
    Lancet. 2021;398:e14.
    >> Share

    August 2021
  26. TIAN M, Zhang Z, Yuan Y
    When a young hepatobiliary surgeon faces his own liver lesions diagnosis.
    Lancet. 2021;398:746.
    >> Share

    April 2021
  27. POWELL EE, Wong VW, Rinella M
    Non-alcoholic fatty liver disease.
    Lancet. 2021 Apr 21. pii: S0140-6736(20)32511.
    >> Share

    March 2021
  28. WILLIAMS R, Alessi C, Alexander G, Allison M, et al
    New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.
    Lancet. 2021 Mar 10. pii: S0140-6736(20)32396.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016